eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
vol. 26
Review paper

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

Aneta Nitsch-Osuch
Piotr Jankowski
Joanna Kokoszka-Paszkot
Ernest Kuchar
Agnieszka Mastalerz-Migas
Przemysław Mitkowski
Jacek Wysocki
Agnieszka Zmysłowska
Adam Antczak

  1. Department of Social Medicine and Public Health, Warsaw Medical University, Warsaw, Poland; Polish Society of Family Medicine
  2. Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland; Polish Cardiac Society
  3. Internal Medicine and Geriatrics Department, H. Klimontowicz Hospital, Gorlice, Poland; Polish Gerontology Society
  4. Department of Pediatrics with Clinical Decisions Unit, Medical University of Warsaw, Warsaw, Poland; Polish Vaccinology Society; National Infectious Diseases Prevention Program
  5. Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; Polish Society of Family Medicine; National Infectious Diseases Prevention Program
  6. Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland; Polish Cardiac Society
  7. Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland; Polish Vaccinology Society
  8. Department of Clinical Genetics, Medical University of Lodz, Lodz, Poland; Polish Diabetes Association
  9. Department of General and Oncological Pulmonology, Medical Univer-sity of Lodz, Lodz, Poland; National Infectious Diseases Prevention Program
Family Medicine & Primary Care Review 2024; 26(1): 116–122
Online publish date: 2024/01/31
Get citation
PlumX metrics:
1. Paules CI, Fauci AS. Influenza vaccines: good, but we can do better. J Infect Dis 2019; 219(Suppl. 1): S1–S4.
2. WHO. Influenza (Seasonal) 2023 [cited 03.10.2023]. Available from URL: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
3. Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med 2014; 2(6): 445–454.
4. GBD 2017 Influenza Collaborators. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2019; 7: 69–89, doi: 10.1016s2213-260030496-x.
5. Macias AE, McElhaney JE, Chaves SS, et al. The disease burden of influenza beyond respiratory illness. Vaccine 2021; 39(Suppl. 1): A6–A14, doi: 10.1016/j.vaccine.2020.09.048.
6. WHO. Influenza [cited 28.05.2009]. Available from URL: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/influenza.
7. Sezon grypowy 2022/2023: liczba zachorowań na grypę i zgonów. Puls Medycyny 2023 [cited 31.05.2023]. Available from URL: https://pulsmedycyny.pl/sezon-grypowy-2022-2023-liczba-zachorowan-na-grype-i-zgonow-1173692 (in Polish).
8. Meldunki epidemiologiczne “Zachorowania i podejrzenia zachorowań na grypę w Polsce” [cited 03.07.2023]. Available from URL: http://wwwold.pzh.gov.pl/oldpage/epimeld/grypa/index.htm (in Polish).
9. Buchy P, Badur S. Who and when to vaccinate against influenza. Int J Infect Dis 2020; 93: 375–387, doi: 10.1016/j.ijid.2020.02.040.
10. McElhaney JE, Verschoor CP, Andrew MK, et al. The immune response to influenza in older humans: beyond immune senescence. Immun Ageing 2020; 17: 10, doi: 10.1186/s12979-020-00181-1.
11. Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 2018; 391(10127): 1285–300, doi: 10.1016/s0140-6736(17)33293-2.
12. Paget J, Staadegaard L, Wang X, et al. Global and national influenza-associated hospitalisation rates: Estimates for 40 countries and administrative regions. J Glob Health 2023; 13: 04003, doi: 10.7189/jogh.13.04003.
13. Andrew MK, Gilca V, Waite N, et al. Examining the knowledge, Attitudes and experiences of Canadian seniors Towards influenza (the EXACT survey). BMC Geriatrics 2019; 19: 1–9.
14. Alvarez FP, Chevalier P, Borms M, et al. Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal. J Med Econ 2023; 26(1): 710–719, doi: 10.1080/13696998.2023.2194193.
15. Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers 2018; 4(1): 3, doi: 10.1038/s41572-018-0002-y.
16. Vetrano DL, Triolo F, Maggi S, et al. Fostering healthy aging: The interdependency of infections, immunity and frailty. Ageing Res Rev 2021; 69: 101351, doi: 10.1016/j.arr.2021.101351.
17. Wilhelm M. Influenza in older patients: a call to action and recent updates for vaccinations. Am J Manag Care 2018; 24(2 Suppl): S15–S24.
18. Villar-Álvarez F, de la Rosa-Carrillo D, Fariñas-Guerrero F, et al. Immunosenescence, Immune Fitness and Vaccination Schedule in the Adult Respiratory Patient. Open Respir Arch 2022; 4(3): 100181, doi: 10.1016/j.opresp.2022.100181.
19. Jabłońska MK. Immunoaging – impact of aging on the components of the immune system. Gerontol Pol 2013; 4: 143–147.
20. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011; 10(4): 430–439, doi: 10.1016/j.arr.2011.03.003.
21. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37–43.
22. Low LL, Kwan YH, Ko MSM, et al. Epidemiologic Characteristics of Multimorbidity and Sociodemographic Factors Associated With Multimorbidity in a Rapidly Aging Asian Country. JAMA Netw Open 2019; 2(11): e1915245, doi: 10.1001/jamanetworkopen.2019.15245. Erratum in: JAMA Netw Open 2021; 4(2): e211476.
23. Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J 2014; 44(4): 1055–1068, doi: 10.1183/09031936.00059814.
24. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging 2014; 9: 433–441, doi: 10.2147/CIA.S45300.
25. Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol 2018; 15: 505–522.
26. Welch C, Hassan-Smith ZK, Greig CA, et al. Acute sarcopenia secondary to hospitalisation – an emerging condition affecting older adults. Aging Dis 2018; 9: 151–164.
27. Barnes M, Heywood AE, Mahimbo A, et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart 2015; 101: 1738–1747.
28. Peteranderl C, Herold S, Schmoldt C. Human Influenza Virus Infections. Semin Respir Crit Care Med 2016; 37(4): 487–500, doi: 10.1055/s-0036-1584801.
29. Trombetta CM, Gianchecchi E, Montomoli E. Influenza vaccines: Evaluation of the safety profile. Hum Vaccin Immunother 2018; 14(3): 657–670, doi: 10.1080/21645515.2017.1423153.
30. Torner N, Martínez A, Basile L, et al. Program Of Catalonia TP. Influenza vaccine effectiveness assessment through sentinel virological data in three post-pandemic seasons. Hum Vaccin Immunother 2015; 11(1): 225–230, doi: 10.4161/hv.36155.
31. CDC Estimated Influenza Illnesses, Medical visits, and Hospitalizations Prevented by Vaccination in the United States – 2019–2020 Influenza Season. 2022 [cited 29.12.2023]. Available from URL: https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm.
32. Cohen SA, Chui KK, Naumova EN. Influenza vaccination in young children reduces influenza-associated hospitalizations in older adults, 2002–2006. J Am Geriatr Soc 2011; 59: 327–332.
33. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 2013; 12(9): 1085–1094, doi: 10.1586/14760584.2013.824709.
34. Clements ML, Murphy BR. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986; 23(1): 66–72.
35. Moa AM, Chughtai AA, Muscatello DJ, et al. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine 2016; 34(35): 4092–4102, doi: 10.1016/j.vaccine.2016.06.064.
36. Carregaro RL, Roscani ANCP, Raimundo ACS, et al. Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews. BMC Infect Dis 2023; 23(1): 563, doi: 10.1186/s12879-023-08541-0.
37. Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people: An umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. Ageing Res Rev 2020; 62: 101118, doi: 10.1016/j.arr.2020.101118.
38. Smetana J, Chlibek R, Shaw J, et al. Influenza vaccination in the elderly. Hum Vaccin Immunother 2018; 14(3): 540–549, doi: 10.1080/21645515.2017.1343226.
39. Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J Epidemiol 1976; 104(1): 47–59, doi: 10.1093/oxfordjournals.aje.a112273.
40. Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of influenza vaccination in specific populations children and the elderly. Expert Rev Vaccines 2012; 11(8): 973–984.
41. McLean HQ, Belongia EA. Influenza Vaccine Effectiveness: New Insights and Challenges. Cold Spring Harb Perspect Med 2021; 11(6): a038315, doi: 10.1101/cshperspect.a038315.
42. Balasubramani GK, Nowalk MP, Sax TM, et al. Influenza vaccine effectiveness among outpatients in the US Influenza Vaccine Effectiveness Network by study site 2011-2016. Influenza Other Respir Viruses 2020; 14(4): 380–390, doi: 10.1111/irv.12741.
43. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16(8): 942–951, doi: 10.1016/S1473-3099(16)00129-8.
44. Zimmerman RK, Nowalk MP, Chung J, et al. US Flu VE Investigators; U.S. Flu VE Investigators. 2014–2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis 2016; 63(12): 1564–1573, doi: 10.1093/cid/ciw635.
45. Martins JP, Santos M, Martins A, et al. Seasonal Influenza Vaccine Effectiveness in Persons Aged 15–64 Years: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2023; 11(8): 1322, doi: 10.3390/vaccines11081322.
46. Russell K, Chung JR, Monto AS, et al. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons. Vaccine 2018; 36: 1272–1278.
47. Pebody RG, Warburton F, Andrews N, et al. Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17. Euro Surveill 2018; 23(39), doi: 10.2807/1560-7917.ES.2018.23.39.1800092.
48. Rondy M, El Omeiri N, Thompson MG, et al. Effectiveness of influenza vaccines in preventing severe influenza illness among adults: a systematic review and meta-analysis of test-negative design case–control studies. J Infect 2017; 75: 381–394.
49. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24(8): 1159–1169, doi: 10.1016/j.vaccine.2005.08.105.
50. Osterholm MT, Kelley NS, Sommer A, et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12(1): 36–44.
51. Praditsuwan R, Assantachai P, Wasi C, et al. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 2005; 88: 256–264.
52. Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 1994; 272: 1661–1665.
53. Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518–527.
54. Seasonal influenza vaccines. ECDC 2023 [cited 27.10.2023]. Available from URL: https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/seasonal-influenza-vaccines.
55. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371: 635–645.
56. Lee JKH, Lam GKL, Yin JK, et al. High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine X 2023; 14: 100327, doi: 10.1016/j.jvacx.2023.100327.
57. DiazGranados CA, Robertson CA, Talbot HK, et al. Prevention of serious events in adults 65 years of age or older: a comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015; 33(38): 4988–4993.
58. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis [published correction appears in Lancet Infect Dis 2015; 15: 263]. Lancet Infect Dis 2015; 15: 293–300.
59. Shay DK, Chillarige Y, Kelman J, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing post-influenza deaths during 2012–2013 and 2013–2014. J Infect Dis 2017; 215: 510–517.
60. Chaves SS, Naeger S, Lounaci K, et al. High-Dose Influenza Vaccine Is Associated With Reduced Mortality Among Older Adults With Break-through Influenza Even When There Is Poor Vaccine-Strain Match. Clin Infect Dis 2023; 77(7): 1032–1042, doi: 10.1093/cid/ciad322.
61. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012; 31: 49–57.
62. Tsang P, Gorse GJ, Strout CB, et al. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥ 65 years of age: a randomized, controlled, phase II trial. Vaccine 2014; 32(21): 2507–2517, doi: 10.1016/j.vaccine.2013.09.074.
63. Pepin S, Nicolas JF, Szymanski H, et al. QHD00011 study team. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial. Hum Vaccin Immunother 2021; 17(12): 5475–5486, doi: 10.1080/21645515.2021.1983387.
64. Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200: 172–180.
65. Comber L, O Murchu E, Jordan K, et al. Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥ 18 years of age. Rev Med Virol 2023; 33(3): e2330, doi: 10.1002/rmv.2330.
66. Chang LJ, Meng Y, Janosczyk H, et al. QHD00013 Study Group. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥ 65 years of age: A phase 3 randomized clinical trial. Vaccine 2019; 37(39): 5825–5834, doi: 10.1016/j.vaccine.2019.08.016.
67. Sanchez L, Nakama T, Nagai H, et al. QHD00010 Study Group. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial. Vaccine 2023; 41(15): 2553–2561, doi: 10.1016/j.vaccine.2023.02.071.
68. EMEA-002359-PIP01-18-M05 – paediatric investigation plan [cited 29.06.2023]. Available from URL: https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002359-pip01-18-m05.
69. Summary of product characteristics Efluelda. Available from URL: http://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2131-015-001_23082023123426.pdf.
70. Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices – United States, 2023–24 Influenza Season. MMWR Recomm Rep 2023; 72(2): 1–25, doi: http://dx.doi.org/10.15585/mmwr.rr7202a1.
71. Influenza vaccines: Canadian Immunization Guide [cited 18.12.2023]. Available from URL: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-10-influenza-vaccine.html#a6.4.
72. Dalcin D, Kwong JC. High-dose influenza vaccination. CMAJ 2019; 191(11): E313, doi: 10.1503/cmaj.181477.
73. Pahmeier K, Speckemeier C, Neusser S, et al. Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model. Pharmacoeconomics 2023; 41(11): 1539–1550, doi: 10.1007/s40273-023-01299-y.
74. Doporučení české vakcinologické společnosti ČLS JEP k očkování proti chřipce. 2023 [cited 28.06.2023]. Available from URL: https://www.vakcinace.eu/doporuceni-a-stanoviska/doporuceni-ceske-vakcinologicke-spolecnosti-cls-jep-k-ockovani-proti-chripce-3 (in Czech).
75. Joint Committee on Vaccination and Immunisation Advice on influenza vaccines for 2022/23. 2021. Available from URL: https://www.nitag-resource.org/sites/default/files/2021-10/JCVI%20Statement%20on%20Influenza%20Vaccines%202022-23.pdf.
76. Mastalerz-Migas A, Kuchar E, Nitsch-Osuch A, et al. Recommendations for preventing, diagnosing, and treating influenza in adults for general practitioners: FLU COMPASS GP – ADULTS. Expert recommendations from the Polish Society of Family Medicine, Polish Vaccinology Society and from the Polish National Program against Influenza. Fam Med Prim Care Rev 2020; 22(1): 81–96.
77. Zalecenia kliniczne dotyczące postępowania u osób z cukrzycą 2023 Stanowisko Polskiego Towarzystwa Diabetologicznego Zalecenia kliniczne dla osób z cukrzycą. Available from URL: https://ptdiab.pl/zalecenia-ptd/zalecania-aktywni-czlonkowie-2023 (in Polish).
78. Wytyczne ESC 2021 dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca. Available from URL: https://ptkardio.pl/wytyczne/44-wytyczne_esc_2021_dotyczace_diagnostyki_i_leczenia_ostrej_i_przewleklej_niewydolnosci_serca (in Polish).
79. Komunikat Głównego Inspektora Sanitarnego z dnia 28 października 2022 r. w sprawie Programu Szczepień Ochronnych na rok 2023. Available from URL: https://dziennikmz.mz.gov.pl/DUM_MZ/2022/113/oryginal/akt.pdf (in Polish).
80. Ogólnopolski Program Zwalczania Chorób Infekcyjnych. Raport epidemiologiczny – HPV, grypa, Covid-19, pneumokoki 2023_PRESS. Available from URL: www.opzci.pl (in Polish).
81. OECD (2023), Influenza vaccination rates (indicator), doi: 10.1787/e452582e-en [cited 23.10.2023]. Available from URL: https://data.oecd.org/healthcare/influenza-vaccination-rates.htm.
82. The situation of older people in Poland in 2020. Gus 2021. Available from URL: https://stat.gov.pl/files/gfx/portalinformacyjny/en/defaultaktualnosci/3618/1/3/1/the_situation_of_older_people_in_poland_in_2020.pdf.
83. Piotrowicz K, Pac A, Skalska A, et al. Patterns of multimorbidity in 4588 older adults: implications for a nongeriatrician specialist. Pol Arch Intern Med 2021; 131(12): 16128, doi: 10.20452/pamw.16128.
Copyright: © 2024 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.